Abstract
The article focuses on the challenges faced by the Collaboration Agreement of Drug Regulatory Authorities in European Union Associated Countries (CADREAC) in harmonization with European Union pharmaceutical standards. The beneficial impact of different forms of collaboration and the national acheivements of the Bulgarian Drug Agency are reviewed. In the harmonization process, drug regulatory authorities are dedicated to collaborating with all stakeholders, starting with industry and ending with consumers.
Keywords
Get full access to this article
View all access options for this article.
